Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A

التفاصيل البيبلوغرافية
العنوان: Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A
المؤلفون: Marc Suetterlin, Frank Hofmann, Angela Boch, Frederik Wenz, Elena Sperk, Uta Kraus-Tiefenbacher, Axel Gerhardt, Grit Welzel
المصدر: Radiation Oncology (London, England)
بيانات النشر: Springer Science and Business Media LLC, 2013.
سنة النشر: 2013
مصطلحات موضوعية: Quality of life, Adult, medicine.medical_specialty, Cross-sectional study, medicine.medical_treatment, Breast Neoplasms, law.invention, Breast cancer, Randomized controlled trial, TARGIT-A trial, law, medicine, Humans, Radiology, Nuclear Medicine and imaging, Stage (cooking), Boost, Aged, Aged, 80 and over, Radiotherapy, business.industry, Research, Cancer, Targeted intraoperative radiotherapy, Middle Aged, medicine.disease, Surgery, Clinical trial, Radiation therapy, Cross-Sectional Studies, Oncology, Radiology Nuclear Medicine and imaging, Female, business
الوصف: Background Intraoperative radiotherapy (IORT) is a new treatment approach for early stage breast cancer. This study reports on the effects of IORT on radiation-related quality of life (QoL) parameters. Methods Two hundred and thirty women with stage I-III breast cancer (age, 31 to 84 years) were entered into the study. A single-center subgroup of 87 women from the two arms of the randomized phase III trial TARGIT-A (TARGeted Intra-operative radioTherapy versus whole breast radiotherapy for breast cancer) was analyzed. Furthermore, results were compared to non-randomized control groups: n = 90 receiving IORT as a tumor bed boost followed by external beam whole breast radiotherapy (EBRT) outside of TARGIT-A (IORT-boost), and n = 53 treated with EBRT followed by an external-beam boost (EBRT-boost). QoL was collected using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires C30 (QLQ-C30) and BR23 (QLQ-BR23). The mean follow-up period in the TARGIT-A groups was 32 versus 39 months in the non-randomized control groups. Results Patients receiving IORT alone reported less general pain (21.3 points), breast (7.0 points) and arm (15.1 points) symptoms, and better role functioning (78.7 points) as patients receiving EBRT (40.9; 19.0; 32.8; and 60.5 points, respectively, P < 0.01). Patients receiving IORT alone also had fewer breast symptoms than TARGIT-A patients receiving IORT followed by EBRT for high risk features on final pathology (IORT-EBRT; 7.0 versus 29.7 points, P < 0.01). There were no significant differences between TARGIT-A patients receiving IORT-EBRT compared to non-randomized IORT-boost or EBRT-boost patients and patients receiving EBRT without a boost. Conclusions In the randomized setting, important radiation-related QoL parameters after IORT were superior to EBRT. Non-randomized comparisons showed equivalent parameters in the IORT-EBRT group and the control groups.
تدمد: 1748-717X
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::462ed574df07111bfa766c4c8b7f7719Test
https://doi.org/10.1186/1748-717x-8-9Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....462ed574df07111bfa766c4c8b7f7719
قاعدة البيانات: OpenAIRE